BGNE: beigene.com Price/Earnings to Growth Multiple
BeiGene, Ltd. (BGNE) dominates the oncology sector through colossal R&D investments and its own proprietary trial networks. The PEG ratio confirms this expansion, with the parameter stabilizing at 0.54. A steady cash flow from flagship drugs is further bolstered by protection via strict FDA and NMPA oversight, creating insurmountable barriers to entry for new players.
Analytical breakdowns for BeiGene, Ltd. (BGNE)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
BGNE - Net Profit|Expected Net Profit BeiGene, Ltd.|BGNE - Price to Earnings Ratio|Price to Future Earnings Ratio BeiGene Ltd|BGNE - PEG Multiple|Company Value to EBITDA BeOne Medicines|BGNE - Operating profit before deduction of amortization|Earnings per share for the trailing year BeiGene|BGNE - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months beigene.com|BGNE - Net earnings per share growth this year|Projected earnings per share increase next year BeiGene, Ltd.
- total revenue and sales volume data:
General company analysis:BGNE - BeiGene Ltd.
The efficiency of global oncology drug delivery chains for BeiGene, Ltd. (BGNE) directly impacts business scaling rates and profit dynamics. By analyzing the price-to-earnings ratio relative to EPS growth, an investor assesses the cost of each unit of profit increase, where a value below one signals that the asset is undervalued relative to its expansion. This chart enables the rapid identification of potential breakout potential or, conversely, the stagnation of the company's growth drivers.
Competing companies
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|PEG Multiple DCTH|Price/Earnings to Growth Ratio YMAB (ymabs.com)|PEG Multiple AURA (Aura Biosciences)|Candel Therapeutics Inc. (CADL) - Price to Earnings Adjusted for Growth Rate|Accuray Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income SELLAS Life Sciences SLS|ACTU: PEG Multiple|Price to Net Income Growth Ratio citiusonc.com CTOR|HURA (TuHURA Biosciences Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Protara Therapeutics Inc TARA|Price/Earnings to Growth Ratio Fate Therapeutics Corp (FATE)|aadibio.com - Growth-Adjusted P/E Ratio|PEG Multiple TCRX (TScan Therapeutics, Inc.)|Champions Oncology Inc (CSBR) - Price to Earnings Adjusted for Growth Rate|XBIT: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio CVM (CEL-SCI Corporation)|OS Therapies Inc (OSTX) - Price/Earnings to Growth Ratio|RADX (Radiopharm Theranostics Ltd) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple ARTV|ANL (Adlai Nortye Limited) - Company Value to Earnings Growth Ratio|PEG Multiple VERU|Tempest Therapeutics Inc - Growth-Adjusted P/E Ratio|Xilio Therapeutics - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Renovaro Biosciences (RENB)|Mural Bio - PEG Multiple|KAPA: Price/Earnings to Growth Ratio|OKUR: PEG Multiple|Price to Net Income Growth Ratio CytoMed Therapeutics Limited GDTC|Price/Earnings to Growth Ratio Curis Inc.|Growth-Adjusted P/E Ratio APLM (Apollomics Corp)|PEG Multiple THAR|ADVB - Price to Earnings Adjusted for Growth Rate|PEG Multiple GNPX (Genprex)|CLDI - Price/Earnings to Growth Multiple|Sunshine Biopharma - PEG Multiple|XBIO - PEG Multiple|Salarius Pharmaceuticals (SLRX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio PPBT|AONC (American Oncology Network Inc) - PEG Multiple|Price/Earnings to Growth Multiple Checkpoint Therapeutics Inc. (CKPT)|PEG Multiple ELEV|ICAD - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Ikena Oncology IKNA|Growth-Adjusted Payback Ratio NTBL|VIRX: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio MOR (MorphoSys Inc)|NAYA: PEG Multiple|Price/Earnings to Growth Multiple Ascentage
